ClinicalTrials.gg
CompletedNCT01634191Updated Apr 14, 2021Results posted

Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy Adults

A Phase 1 interventional study of Apremilast in Healthy Volunteer, sponsored by Amgen. Completed at 2 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-14.

Sponsored by Amgen · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Feb 2012, registered Jul 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the effects of age and sex on the pharmacokinetics and safety of a single oral dose of 30 mg apremilast in healthy adults.

Read the detailed description

This is an open-label, parallel group study where eligible elderly adults (aged 65-85 years inclusive) and younger adults (aged 18-55 years inclusive) and who are matched to the elderly participants by sex and body mass index (BMI) (± 10%) will receive a single dose of 30 mg apremilast under fasting conditions.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Apremilast
  • pharmacokinetic
  • safety
  • Pharmacokinetics and safety in healthy volunteer subjects
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria for elderly group

  1. Healthy male or female subjects of any ethnic origin between ages of 65 and 85 inclusive with a (BMI) between 18 and 35.
  2. Females must have been surgically sterilized at least 6 months prior to screening or be (to be confirmed by lab tests).
  3. Males must agree to use latex or polyurethane condoms when engaging in sex during the study and for at least 28 days after dosing.
  4. Elderly subjects with stable, chronic medical condition may be eligible if the condition is well-controlled and medications do not interfere with study procedures or pharmacokinetic interpretation

Inclusion Criteria for younger group:

  1. Healthy male or female of any ethnic origin between the ages of 18 and 55 inclusive with a BMI between 18 and 35.
  2. Males must agree to use latex or polyurethane condoms when engaging in sex during the study and for at least 28 days after dosing.
  3. Females who are able to become pregnant have a negative pregnancy test at screening and baseline, and must agree to use one of the following:

    • a highly effective form of (ex. Non-oral hormonal, intrauterine device) OR
    • oral hormonal contraceptive plus one additional form of barrier contraception OR
    • two forms of barrier contraception These must be effective by the time of screening. For younger females who are not able to become pregnant, the conditions for the elderly females will apply.

Exclusion Criteria:

  1. Any condition, including the presence of laboratory abnormalities, or psychiatric illness, that would prevent the subject from signing the form, places the subject at unacceptable risk if he were to participate in the study, or confounds the ability to interpret data from the study.
  2. Presence of any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism, and excretion, or plans to have elective or medical procedures during the conduct of the trial.
  3. Exposure to an drug (new chemical entity) within 30 days prior to the first dose administration or 5 half-lives of that investigational drug, if known (whichever is longer).
  4. Subjects with known serum hepatitis, is a known carrier of surface antigen, antibody, or antibody.
  5. Subjects who have used prescription systemic or topical medications within 30 days of dosing, unless it is being used to treat a stable, chronic medical condition. This includes medication that is an inhibitor or inducer of P-glycoprotein transporter and CYP-3A4/5 used within 14 days of dosing.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Elderly: Apremilast 30 mg

    Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.

    Drug: Apremilast

  • Experimental
    Younger: Apremilast 30 mg

    Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.

    Drug: Apremilast

Interventions

  • One oral 30 mg dose of apremilast

    Also known as: CC-10004, Otezla®

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast

    The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL. AUC0-t was calculated using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing.

    Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.

  2. AUC From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast by Sex

    The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL. AUC0-t was calculated using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing.

    Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.

  3. Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast

    The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.

    Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.

  4. AUC From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast by Sex

    The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.

    Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.

  5. Maximum Observed Plasma Concentration (Cmax) of Apremilast

    The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.

    Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.

  6. Maximum Observed Plasma Concentration of Apremilast by Sex

    The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.

    Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.

  7. Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast

    The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.

    Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.

  8. Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast by Sex

    The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.

    Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.

  9. Estimate of Terminal Elimination Half-life of Apremilast in Plasma (t1/2)

    Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.

  10. Estimate of Terminal Elimination Half-life of Apremilast in Plasma by Sex

    Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.

  11. Apparent Total Plasma Clearance When Dosed Orally (CL/F) of Apremilast

    Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.

  12. Apparent Total Plasma Clearance When Dosed Orally of Apremilast by Sex

    Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.

  13. Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast

    Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.

  14. Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast by Sex

    Time frame: Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.

Secondary outcomes

  1. Number of Participants With Adverse Events

    An adverse event (AE) was any noxious, unintended, or untoward medical occurrence that appeared or worsened in a participant during the course of the study. It could have been a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a pre-existing condition) was considered an AE.

    Time frame: From first dose of study drug up to 11 days

07

Results

Posted Apr 14, 2021

Participant flow

This study was conducted at two clinical research sites in the United States.

Participant flow — Overall Study
MilestoneYoung: Apremilast 30 mgElderly: Apremilast 30 mg
Started1818
Completed1818
Not completed00

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast

The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL. AUC0-t was calculated using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing.

Time frame:
Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast
h*ng/mLYoung: ApremilastElderly: Apremilast
Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast2832 ± 28.13235 ± 40.3
Statistical analysis
  • Young: Apremilast vs Elderly: Apremilast · Geometric mean ratio: 113 · 90% CI 94.2 to 135Geometric mean ratio (Elderly/Young) and 90% confidence interval (CI) of the ratio calculated from a 2-way ANOVA model, and presented as percentages.
SecondaryNumber of Participants With Adverse Events

An adverse event (AE) was any noxious, unintended, or untoward medical occurrence that appeared or worsened in a participant during the course of the study. It could have been a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health including laboratory test values, regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a pre-existing condition) was considered an AE.

Time frame:
From first dose of study drug up to 11 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsYoung MalesYoung FemalesElderly MalesElderly Females
Any adverse event2125
Adverse event related to study drug2101
Serious adverse events0000
Serious adverse events related to study drug0000
Discontinued due to adverse event0000
Discontinued due to adverse event related to study drug0000
PrimaryAUC From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast by Sex

The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL. AUC0-t was calculated using the linear trapezoidal method when concentrations were increasing and the logarithmic trapezoidal method when concentrations were decreasing.

Time frame:
Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Reported as:
Geometric mean · h*ng/mL
AUC From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast by Sex
h*ng/mLMales (Combined)Females (Combined)
AUC From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Apremilast by Sex2634 ± 24.53382 ± 38.2
Statistical analysis
  • Males (Combined) vs Females (Combined) · Geometric mean ratio: 128 · 90% CI 107 to 154Geometric mean ratio (Female/Male) and 90% CI of the ratio calculated from a 2-way ANOVA model, and presented as percentages.
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast

The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.

Time frame:
Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast
h*ng/mLYoung: ApremilastElderly: Apremilast
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast2900 ± 28.73323 ± 41.8
Statistical analysis
  • Young: Apremilast vs Elderly: Apremilast · Geometric mean ratio: 113 · 90% CI 94.1 to 135Geometric mean ratio (Elderly/Young) and 90% CI of the ratio calculated from a 2-way ANOVA model, and presented as percentages.
PrimaryAUC From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast by Sex

The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.

Time frame:
Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Reported as:
Geometric mean · h*ng/mL
AUC From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast by Sex
h*ng/mLMales (Combined)Females (Combined)
AUC From Time Zero Extrapolated to Infinity (AUC0-∞) of Apremilast by Sex2673 ± 24.83499 ± 39.1
Statistical analysis
  • Males (Combined) vs Females (Combined) · Geometric mean ratio: 131 · 90% CI 109 to 157Geometric mean ratio (Female/Male) and 90% CI of the ratio calculated from a 2-way ANOVA model, and presented as percentages.
PrimaryMaximum Observed Plasma Concentration (Cmax) of Apremilast

The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.

Time frame:
Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Apremilast
ng/mLYoung: ApremilastElderly: Apremilast
Maximum Observed Plasma Concentration (Cmax) of Apremilast302 ± 26.8321 ± 27.8
Statistical analysis
  • Young: Apremilast vs Elderly: Apremilast · Geometric mean ratio: 106 · 90% CI 90.5 to 123Geometric mean ratio (Elderly/Young) and 90% CI of the ratio calculated from a 2-way ANOVA model, and presented as percentages.
PrimaryMaximum Observed Plasma Concentration of Apremilast by Sex

The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.

Time frame:
Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration of Apremilast by Sex
ng/mLMales (Combined)Females (Combined)
Maximum Observed Plasma Concentration of Apremilast by Sex299 ± 16.6322 ± 33.5
Statistical analysis
  • Males (Combined) vs Females (Combined) · Geometric mean ratio: 108 · 90% CI 92.3 to 126Geometric mean ratio (Female/Male) and 90% CI of the ratio calculated from a 2-way ANOVA model, and presented as percentages.
PrimaryTime to Maximum Observed Plasma Concentration (Tmax) of Apremilast

The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.

Time frame:
Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast
hoursYoung: ApremilastElderly: Apremilast
Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast2.50 (0.5 to 5.0)2.50 (1.0 to 5.1)
Statistical analysis
  • Young: Apremilast vs Elderly: Apremilast · Wilcoxon rank-sum test · p = 0.153 · Median difference: 0.500 · 90% CI 0.000 to 2.00Median difference (Elderly - Young) calculated from the Hodges-Lehmann estimate.
PrimaryTime to Maximum Observed Plasma Concentration (Tmax) of Apremilast by Sex

The lower limit of quantitation for apremilast plasma concentrations was 1.0 ng/mL.

Time frame:
Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast by Sex
hoursMales (Combined)Females (Combined)
Time to Maximum Observed Plasma Concentration (Tmax) of Apremilast by Sex2.5 (0.5 to 5.0)2.75 (1.0 to 5.1)
Statistical analysis
  • Males (Combined) vs Females (Combined) · Wilcoxon rank-sum test · p = 0.169 · Median difference: 0.500 · 90% CI 0.000 to 2.00Median difference (Female - Male) and 90% CI of the difference calculated from the Hodges-Lehmann estimate.
PrimaryEstimate of Terminal Elimination Half-life of Apremilast in Plasma (t1/2)
Time frame:
Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Reported as:
Mean · hours
Estimate of Terminal Elimination Half-life of Apremilast in Plasma (t1/2)
hoursYoung: ApremilastElderly: Apremilast
Estimate of Terminal Elimination Half-life of Apremilast in Plasma (t1/2)9.41 ± 2.659.15 ± 2.56
PrimaryEstimate of Terminal Elimination Half-life of Apremilast in Plasma by Sex
Time frame:
Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Reported as:
Mean · hours
Estimate of Terminal Elimination Half-life of Apremilast in Plasma by Sex
hoursMales (Combined)Females (Combined)
Estimate of Terminal Elimination Half-life of Apremilast in Plasma by Sex8.06 ± 1.7210.3 ± 2.76
PrimaryApparent Total Plasma Clearance When Dosed Orally (CL/F) of Apremilast
Time frame:
Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Reported as:
Geometric mean · L/hr
Apparent Total Plasma Clearance When Dosed Orally (CL/F) of Apremilast
L/hrYoung: ApremilastElderly: Apremilast
Apparent Total Plasma Clearance When Dosed Orally (CL/F) of Apremilast10.4 ± 28.79.03 ± 41.8
PrimaryApparent Total Plasma Clearance When Dosed Orally of Apremilast by Sex
Time frame:
Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Reported as:
Geometric mean · L/hr
Apparent Total Plasma Clearance When Dosed Orally of Apremilast by Sex
L/hrMales (Combined)Females (Combined)
Apparent Total Plasma Clearance When Dosed Orally of Apremilast by Sex11.2 ± 24.88.57 ± 39.1
PrimaryApparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast
Time frame:
Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Reported as:
Geometric mean · liters
Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast
litersYoung: ApremilastElderly: Apremilast
Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast136 ± 38.9115 ± 35.3
PrimaryApparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast by Sex
Time frame:
Day 1 predose and at 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 24, 36, and 48 hours after dosing.
Reported as:
Geometric mean · liters
Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast by Sex
litersMales (Combined)Females (Combined)
Apparent Total Volume of Distribution When Dosed Orally (Vz/F) of Apremilast by Sex128 ± 30.7123 ± 43.4

Adverse events

Collected over From first dose of apremilast up to 11 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Young Males—0/8 (0%)2/8 (25%)
Young Females—0/10 (0%)1/10 (10%)
Young (Total)—0/18 (0%)3/18 (16.7%)
Elderly Males—0/8 (0%)2/8 (25%)
Elderly Females—0/10 (0%)5/10 (50%)
Elderly (Total)—0/18 (0%)7/18 (38.9%)
Overall Total—0/36 (0%)10/36 (27.8%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventYoung MalesYoung FemalesYoung (Total)Elderly MalesElderly FemalesElderly (Total)Overall Total
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations0/80/100/180/82/102/182/36
CONSTIPATIONGastrointestinal disorders0/80/100/181/80/101/181/36
HEADACHENervous system disorders1/80/101/180/80/100/181/36
SOMNOLENCENervous system disorders1/80/101/180/80/100/181/36
PHLEBITISVascular disorders0/80/100/181/80/101/181/36
NAUSEAGastrointestinal disorders0/81/101/180/81/101/182/36
TOOTHACHEGastrointestinal disorders0/80/100/180/81/101/181/36
VOMITINGGastrointestinal disorders0/81/101/180/80/100/181/36
PAINGeneral disorders0/80/100/180/81/101/181/36
ARTHRALGIAMusculoskeletal and connective tissue disorders0/80/100/180/81/101/181/36

Baseline characteristics

Age, Continuous
Age, Continuous(years)Young MalesYoung FemalesElderly MalesElderly FemalesTotal
Mean33.3 ± 7.4835.2 ± 7.1970.4 ± 3.6270.6 ± 4.7252.4 ± 19.23
Sex: Female, Male
Sex: Female, Male(Participants)Young MalesYoung FemalesElderly MalesElderly FemalesTotal
Female01001020
Male808016
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Young MalesYoung FemalesElderly MalesElderly FemalesTotal
Hispanic or Latino02002
Not Hispanic or Latino8881034
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Young MalesYoung FemalesElderly MalesElderly FemalesTotal
White448824
Black or African American360211
Other10001
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Young MalesYoung FemalesElderly MalesElderly FemalesTotal
Mean26.6 ± 2.4327.5 ± 2.5926.3 ± 2.6927.1 ± 2.4226.9 ± 2.47
08

Study locations

2 sites
  • PRA International
    Lenexa, Kansas 66219, United States
  • Clinical Development Services
    Dallas, Texas 75247, United States
09

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2012 to primary completion in Mar 2012, 1 month.

Results were first posted in Apr 2021, 9 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2012
First posted
Jul 6, 2012
StartActual
Feb 1, 2012
Primary completionActual
Mar 1, 2012
CompletionActual
Apr 1, 2012
Results first posted
Apr 14, 2021
Last update
Apr 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01634191
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jul 6, 2012
Start date
Feb 1, 2012
Primary completion
Mar 1, 2012
Completion
Apr 1, 2012
Results posted
Apr 14, 2021
Last update
Apr 14, 2021

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion